Skip to Main Navigation
Skip to Page Content
COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC and research information from NIH.

U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:
https://ntp.niehs.nih.gov/go/9548

1,3-Butadiene: Target Organs and Levels of Evidence for TR-434

Toxicology and Carcinogenesis Studies of 1,3-Butadiene (CASRN 106-99-0) in B6C3F1 Mice (Inhalation Studies)

Chemical (Study Title)
CASRN		Peer Review DateRoute/Exposure LevelsStudy Laboratory
1,3-Butadiene
106-99-0		11/21/1991Inhalation
0, 6.25, 20, 62.5, 200, 625 PPM/50 PER GROUP		Battelle Northwest Laboratory

Levels of Evidence

Male Mice: Clear Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Hematopoietic System: LYMPHOMA 4/50 2/50 4/50 6/50 2/50 51/73, STOP STUDY 8/50 22/50 8/50 33/50; HISTIOCYTIC SARCOMA 0/50 0/50 4/50 5/50 7/50 4/73, STOP STUDY 5/50 2/50 7/50 2/50
  • Vascular System (Heart): HEMANGIOSARCOMA 0/50 0/49 1/50 5/48 20/48 4/73, STOP STUDY 15/50 7/50 33/50 13/50
  • Lung: ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, OR CARCINOMA 21/50 23/50 19/50 31/49 35/50 3/73, STOP STUDY 36/50 28/50 32/50 17/50
  • Forestomach: SQUAMOUS CELL PAPILLOMA OR CARCINOMA 1/50 0/50 0/50 1/50 8/50 4/73, STOP STUDY 3/50 7/50 9/50 10/50
  • Liver: ADENOMA OR CARCINOMA 21/50 23/50 30/50 25/48 33/48 5/72, STOP STUDY 27/49 19/49 19/50 11/50
  • Harderian Gland: ADENOMA OR CARCINOMA 6/50 7/50 9/50 20/50 31/50 6/73, STOP STUDY 27/50 23/50 30/50 13/50
  • Preputial Gland: CARCINOMA 0/50 0/50 0/50 0/50 5/50 0/73, STOP STUDY 1/50 4/50 4/50 3/50
  • Kidney Tubular Cell: ADENOMA 0/50 1/50 0/50 3/48 1/49 0/73, STOP STUDY 4/48 1/50 3/49 1/50
  • Brain: (STOP STUDY) GLIOMA 0/50 2/50 0/50 1/50
May Have Been Related
  • Intestines: CARCINOMA 0/50 1/50 1/50 1/50 2/50 0/73
  • Zymbal Gland: (STOP STUDY) CARCINOMA 1/50 0/50 2/50 2/50
Non-Neoplastic Lesions
  • BONE MARROW: ATROPHY
  • HEART: ENDOTHELIAL HYPERPLASIA, MINERALIZATION; (STOP STUDY) ENDOTHELIAL HYPERPLASIA, MINERALIZATION
  • LUNG: ALVEOLAR EPITHELIAL HYPERPLASIA; (STOP STUDY) ALVEOLAR EPITHELIAL HYPERPLASIA
  • FORESTOMACH: EPITHELIAL HYPERPLASIA; (STOP STUDY) EPITHELIAL HYPERPLASIA
  • HARDERIAN GLAND: HYPERPLASIA; (STOP STUDY) HYPERPLASIA
  • TESTICLE: ATROPHY; (STOP STUDY) ATROPHY
Female Mice: Clear Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Hematopoietic System: LYMPHOMA 6/50 12/50 11/50 7/50 9/50 32/80; HISTIOCYTIC SARCOMA 3/50 2/50 7/50 4/50 7/50 4/80
  • Vascular System (Heart): HEMANGIOSARCOMA 0/50 0/50 0/50 1/49 21/50 23/80
  • Lung: ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, OR CARCINOMA 4/50 15/50 19/50 24/50 25/50 22/78
  • Forestomach: SQUAMOUS CELL PAPILLOMA OR CARCINOMA 0/50 0/50 3/50 2/50 4/50 22/80
  • Liver: ADENOMA OR CARCINOMA 15/49 14/49 15/50 19/50 16/50 2/80
  • Harderian Gland: ADENOMA OR CARCINOMA 8/50 10/50 7/50 15/50 20/50 9/80
  • Ovary: BENIGN OR MALIGNANT GRANULOSA CELL TUMOR 1/49 0/49 1/48 9/50 8/50 6/79; ADENOMA OR BENIGN MIXED TUMOR 2/49 4/49 1/48 4/50 6/50 2/79
  • Mammary Gland: ADENOACANTHOMA, ADENOCARCINOMA, OR MALIGNANT MIXED TUMOR 0/50 2/50 4/50 12/50 15/50 16/80
May Have Been Related
  • Kidney Tubular Cell: ADENOMA 0/49 0/49 0/48 0/50 2/50 0/80
  • Subcutaneous Tissue: NEUROFIBROSARCOMA OR SARCOMA 1/50 2/50 3/50 5/50 3/50 3/80
  • Zymbal Gland: ADENOMA OR CARCINOMA 0/50 0/50 0/50 0/50 0/50 2/80
Non-Neoplastic Lesions
  • BONE MARROW: ATROPHY
  • HEART: ENDOTHELIAL HYPERPLASIA; MINERALIZATION
  • LUNG: ALVEOLAR EPITHELIAL HYPERPLASIA
  • FORESTOMACH: EPITHELIAL HYPERPLASIA
  • LIVER: FOCI
  • HARDERIAN GLAND: HYPERPLASIA
  • OVARY: ANGIECTASIS; GRANULOSA CELL HYPERPLASIA; GERMINAL EPITHELIAL HYPERPLASIA; ATROPHY
  • UTERUS: ATROPHY